SAN FRANCISCO - (Business Wire) Biomagnetics Diagnostics Corp., (PINK SHEETS:BMGP) a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis, and malaria detection, today announced the Company will hold an investor conference call to discuss upcoming business opportunities and its agreement with one of the world’s premiere research laboratories. The call, which will be open to all investors, will be held on Wednesday, December 2nd at 4:30 EST. Interested parties should contact the Company at info@biomagneticsbmgp.com for invite details. “It is a very exciting time for all of us at Biomagnetics and its shareholders. For the past few quarters we have been working on several major growth initiatives that are now coming to fruition,” commented Clayton Hardman, CEO of Biomagnetics Diagnostics. “Please join us next week as we discuss the pending introduction of our revolutionary technologies for malaria, tuberculosis, HIV and other pathogen and disease diagnosis and as we profile our new and evolving relationship with one of the world’s premiere research institutions. We view our current business opportunities as being highly significant.”
According to the World Health Organization, some 3.2 billion people, or about half the world's population is at risk of malaria transmission in 107 countries and territories worldwide. While there are between 350 million and 500 million new cases of malaria each year, there are very few reliable and field deployable diagnostic tools available. In the case of malaria, early detection substantially improves treatability and survivability. Field deployable Integrated Optical Biosensor System (IBOS), such as those Biomagnetics Diagnostics is planning to soon introduce hold the promise to significantly speed the diagnostic testing process and to meaningfully lower costs and improve lives.
About Biomagnetics Diagnostics Corp.
Biomagnetics Diagnostics Corporation is an advanced medical device and biotechnology company. The Company’s revolutionary diagnostic systems, which are based on advanced magnetics, test for any viral or bacterial disease using any body fluid. The Company's technology allows laboratories to perform far more tests in the same amount of time it takes to do a single test. The HTS-MTP platform is designed to detect the actual virus and viral load in body fluids and not just simply screen for the presence of viral antibodies. More information on Biomagnetics Diagnostics Corp. can be seen at www.BiomagneticsBMGP.com
Biomagnetics Diagnostics Corp.
Joe Noel, 925-922-2560
